Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers

Joan T. Garrett, Cammie R. Sutton, Richard Kurupi, Carl Uli Bialucha, Seth A. Ettenberg, Scott D. Collins, Qing Sheng, Jerry Wallweber, Lisa DeFazio-Elli, and Carlos L. Arteaga

Abstract

We examined the effects of LJM716, an HER3 (ERBB3) neutralizing antibody that inhibits ligand-induced and ligand-independent HER3 dimerization, as a single agent and in combination with BYL719, an ATP competitive p110α-specific inhibitor, against HER2-overexpressing breast and gastric cancers. Treatment with LJM716 reduced HER2-HER3 and HER3-p85 dimers, P-HER3 and P-AKT, both in vitro and in vivo. Treatment with LJM716 alone markedly reduced growth of BT474 xenografts. The combination of LJM716/lapatinib/trastuzumab significantly improved survival of mice with BT474 xenografts compared with lapatinib/trastuzumab (P = 0.0012). LJM716 and BYL719 synergistically inhibited growth in a panel of HER2+ and PIK3CA mutant cell lines. The combination also inhibited P-AKT in HER2-overexpressing breast cancer cells and growth of HER2+ NCI-N87 gastric cancer xenografts more potently than LJM716 or BYL719 alone. Trastuzumab-resistant HER2+/PIK3CA mutant MDA453 xenografts regressed completely after 3 weeks of therapy with LJM716 and BYL719, whereas either single agent inhibited growth only partially. Finally, mice with BT474 xenografts treated with trastuzumab/LJM716, trastuzumab/BYL719, LJM716/BYL719, or trastuzumab/LJM716/BYL719 exhibited similar rates of tumor regression after 3 weeks of treatment. Thirty weeks after treatment discontinuation, 14% of mice were treated with trastuzumab/LJM716/BYL719, whereas >80% in all other treatment groups were sacrificed due to a recurrent large tumor burden (P = 0.0066). These data suggest that dual blockade of the HER2 signaling network with an HER3 antibody that inhibits HER2-HER3 dimers in combination with a p110α-specific inhibitor in the absence of a direct HER2 antagonist is an effective treatment approach against HER2-overexpressing cancers.

Cancer Res; 73(19); 1–11. ©2013 AACR.

Introduction

The phosphatidylinositol 3-kinase (PI3K) pathway is an important regulator in cell survival, proliferation, and apoptosis. PI3K is a major signaling hub downstream of HER2 and other receptor tyrosine kinases (RTK) amplified in cancer cells. PI3K activates AKT, SGK, PDK1, mTOR, and other signaling molecules involved in cell-cycle progression and survival. PI3K is arguably the most frequently somatically altered pathway in cancer (1), with mutation and/or amplification of the genes encoding the PI3K catalytic subunits p110α (PIK3CA) and p110β (PIK3CB), the PI3K regulatory subunit p85α (PIK3R1), the PI3K effectors AKT1-3 and PDK1, RTKs such as HER2 (ERBB2), MET and FGFR1, and loss of the lipid phosphatases PTEN and INPP4B. PIK3CA is activated by growth factor RTKs and G-protein–coupled receptors. PI3K phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) to produce the second messenger phosphatidylinositol 3,4,5-trisphosphate (PIP3), which in turn, potently activates PI3K/AKT. As a result, HER3 is required for HER2 and PI3K-mediated tumorigenesis. For
example, HER3 is activated in breast cancers with HER2 overexpression (6) and coexpression of HER2 and HER3 is associated with decreased patient survival (7). Mammary tumors occurring in mice overexpressing the Neu transgene, the rat homolog of human HER2, exhibit increased expression and phosphorylation of HER3 (8). HER3 is as essential as HER2 for maintaining cell viability in a panel of HER2-overexpressing breast cancer cells (9). In addition, loss of HER3 prevents HER2-mediated transformation of mammary epithelium (10). HER2 is unable to directly bind to and activate p85/p85Δ. Conversely, HER3 contains 6 p85-binding motifs and, when dimerized with and activated by HER2, can potently activate p85Δ (9). Expression of the H1047R PIK3CA mutation in cells that overexpress HER2 upregulates the HER3/HER4 ligand heregulin and knockdown of HER3 inhibits growth of HER2+/p85Δ mutant cells (11). Finally, genetic ablation of HER3 significantly delays tumor formation and reduces metastases in transgenic mice expressing the polyomavirus T antigen in the mammary gland (12), a mouse tumor model where PI3K is also required for transformation (13).

In this study, we used cancer cells and xenografts with different modes of aberrant PI3K pathway activation to examine the effects of LJM716, an HER3 monoclonal antibody that inhibits ligand-induced and ligand-independent HER3 dimerization and activation (14) as a single agent or in combination with BYL719, a p110Δ-specific PI3K inhibitor (15). Treatment with the LJM716 antibody reduced HER2-HER3 and HER3-p85 dimers, P-HER3 and P-AKT, and, as a single agent, delayed growth of HER2+ xenografts. LJM716 and BYL719 synergistically inhibited growth and PI3K in a panel of HER2+ and PIK3CA mutant cell lines. HER2+/PIK3CA mutant, trastuzumab-resistant MDA453 xenografts regressed completely after only 3 weeks of therapy with LJM716 and BYL719 whereas either single agent inhibited growth partially. The combination of trastuzumab/LJM716/BYL719 induced striking regression of large trastuzumab-sensitive BT474 tumors and prolonged survival of mice after discontinuation of treatment. Overall, these data suggest that dual blockade of the HER2 network with an HER3 antibody that inhibits HER2-HER3 dimers in combination with a p110Δ-specific inhibitor in the absence of a direct HER2 antagonist is an effective treatment approach against HER2-overexpressing cancer.

Materials and Methods

Cells and reagents

All cell lines were obtained from American Type Culture Collection (ATCC), maintained in ATCC-recommended media plus 10% FBS (Gibco) and authenticated by short tandem repeat profiling using Sanger sequencing (March 2011). HR6 cells were derived from a trastuzumab-resistant BT474 xenograft in our laboratory and have been described previously (16). The following drugs were used: lapatinib (GW-572016; LC Laboratories), trastuzumab (Vanderbilt University Hospital Pharmacy), and LJM716 and BYL719 (both from Novartis).

Immunoprecipitation and immunoblot assays

Cells were prepared as described (17). Immunoprecipitation was conducted by incubating 500 μg of protein extract with 1 μg of an HER3 C-terminus antibody (Neomarkers) conjugated to biotin and incubated with streptavidin-coupled Dynabeads (Life Technologies) overnight at 4°C. The mixture was washed 5 times in NP-40 lysis buffer and boiled for 5 minutes in 2× loading buffer before being subjected to SDS-PAGE. Lysates were separated by 7% SDS-PAGE and proteins were transferred onto nitrocellulose membranes (Bio-Rad). Primary antibodies included: Y1197 and Y1289 P-HER3, S473, and T308 P-Akt, total Akt, T202/Y204 P-Erk, total Erk, P-GSK3β, P-S6 (all from Cell Signaling), HER3 (Santa Cruz Biotechnology), HER2 (Neomarkers), and β-actin (Sigma). Immuno-reactive bands were detected by enhanced chemiluminescence after incubation with horseradish peroxidase-conjugated secondary antibodies (Promega).

Fluorescent proximity–based antibody-dependent detection (VeraTag) assay

VeraTag assays were conducted on formalin-fixed, paraffin-embedded (FFPE) tumor sections as described previously (18, 19), with modifications (20).

Monolayer and three-dimensional growth assays

The CellTiterGlo Assay was conducted per manufacturer’s instructions (Promega) and details are provided in Supplementary Materials and Methods. For monolayer assay with crystal violet staining, cells were seeded in 6-well plates (5 × 10⁴/well) in 10% FBS-containing medium followed by treatment with inhibitors. Media and inhibitors were replenished every 2 to 3 days until 60% to 80% confluence was achieved in untreated wells. Cells were then stained with crystal violet and quantified as described (21). For growth in three-dimensional (3D), cells were seeded on growth factor–reduced Matrigel (BD Biosciences) in 48-well plates following published protocols (22). Inhibitors were added to the medium at the time of cell seeding; 12 to 16 days later, the plates were scanned and colonies measuring ≥25 μm were counted using GelCount software (Oxford Optronix). Colonies were photographed using an Olympus DP10 camera mounted in an inverted microscope.

Xenograft studies

All mouse experiments were approved by the Institutional Animal Care Committee of Vanderbilt University. Details are provided in Supplementary Materials and Methods.

Results

HER3 antibody inhibits HER3-P3K signaling

We first treated a panel of HER2 gene-amplified human breast cancer cells with LJM716 (14). HR6 cells, derived from BT474 xenografts, are resistant to trastuzumab in vivo and overexpress EGFR and HER3 ligands (16). MDA453, HCC1954, and SUM190 cells contain a mutation in the catalytic domain (H1047R) and MDA361 cells contain a mutation in the helical domain (E545K) of PIK3CA. HCC1569 cells are PTEN-null (23). In all cell lines, the antibody potently inhibited phosphorylation at 2 of the 6 pS6 binding sites in HER3, Tyr-1197, and Tyr-1289, starting at 1 to 24 hours (Fig. 1). This inhibition of P-HR3 translated into inhibition of downstream P-AKT. Notably, HR6...
and HCC1954 cells did not show decreased S473 P-AKT but had modest inhibition of T308 P-AKT. In most cases, there was a recovery of P-AKT at 24 hours after the addition of LJM716. Treatment with LJM716 did not affect P-ERK, suggesting that HER3 signals mainly through the PI3K/AKT pathway. Some cell lines exhibited a reduction in total HER3 (MDA361, SUM190, HCC1954, and MDA453) but this reduction in receptor protein was not uniform and not necessary to see a reduction in P-HER3 and P-AKT levels upon treatment with LJM716. This suggests that the mechanism of action of LJM6716 does not solely involve receptor downregulation.

**LJM716 blocks HER2-HER3 heterodimers**

The crystal structure of HER3 bound to the LJM716 Fab fragment reveals that LJM716 binds to a complex epitope distributed across domains II and IV of the HER3 ectodomain (14). This interaction locks HER3 in a tethered, inactive conformation, where it is unable to dimerize with other members of the ERBB receptor family. Thus, we next examined if LJM716 inhibits HER2/HER3 interactions using a fluorescent antibody–based proximity assay (VeraTag). This assay can quantify protein–protein interactions in FFPE cell pellets or tissue sections and involves the use of 2 monoclonal antibodies, 1 conjugated via a cleavable tether to a fluorescent reporter tag, and the other linked to a photosensitizer molecule. Photoactivation with red light results in release of singlet oxygen that then cleaves the tether and releases the fluorescent tag on the second antibody. The area of influence of the singlet oxygen is limited by the proximity of receptors to which the antibodies are directed (18). The released fluorescent tag can then be collected and quantified using capillary electrophoresis and used as an indicator of levels of protein–protein interaction. Mice bearing BT474 and MDA453 xenografts were treated with 2 doses of 20 mg/kg LJM716 i.p. or vehicle over a 3-day period. Tumors were harvested 4 hours after the second dose of antibody. FFPE tumor sections were subjected to VeraTag analysis of total HER2, total HER3, Y1289 P-HER3, HER2-HER3 dimers, and HER3-p85 (PI3K) dimers. There was not a difference in total HER2 or HER3 between LJM716-treated tumors and controls. However, both tumor types treated with the antibody exhibited a significant reduction in HER2-HER3 dimers and Y1289 P-HER3 compared with untreated xenografts. BT474 but not MDA453 xenografts also showed a reduction in HER3-p85 (PI3K) complexes (Fig. 2A). We next confirmed that the HER3 antibody inhibits ligand-independent HER2-HER3 interactions by immunoprecipitating HER3 from lysates of cells grown in culture in the absence or presence of a saturating concentration of LJM716 for 1 to 4 hours. HER2 immunoblot analysis of HER3 antibody pull-downs showed a clear reduction in HER2 in lysates from BT474 and SKBR3 cells treated with the antibody (Fig. 2B). Consistent with the above-mentioned structural data (14), these results suggest that LJM716 disassembles constitutive HER2-HER3 dimers in intact cells.

**HER3 antibody in combination with trastuzumab and lapatinib improves survival in vivo**

We next assessed the ability of LJM716 to inhibit tumor growth in vivo as a single agent or in combination with HER2 inhibitors. Mice bearing BT474 xenografts measuring ≥200 mm³ were treated with vehicle, LJM716, trastuzumab, trastuzumab/LJM716, lapatinib/trastuzumab, or lapatinib/trastuzumab/LJM716. Treatment with LJM716 alone markedly delayed growth of BT474 xenografts (Fig. 3A). The combination of LJM716/trastuzumab was more active than each antibody
alone. All treatment arms significantly inhibited xenograft growth, particularly lapatinib/trastuzumab, LJM716/trastuzumab, and the 3-drug combination. Mice treated with any of these 3 combinations exhibited a close to complete response with tumors measuring <25 mm³ after 3 weeks of treatment (Fig. 3A). Treatment was stopped at this time and tumor regrowth was monitored. To assess the effect of treatment on survival, mice were followed until they reached a tumor burden of 2,000 mm³, time when they had to be humanely euthanized according to institutional guidelines. At 34 weeks of follow-up with no treatment, less than 40% of mice in the lapatinib/trastuzumab and the LJM716/trastuzumab arms were alive whereas 93% of mice in the lapatinib/trastuzumab/LJM716 group were so (P = 0.0012, log-rank test; Fig. 3B).

HER3 antibody synergizes with p110α inhibitor against HER2+ tumor cells

We speculated that a combination of a p110α-specific inhibitor and the HER3 antibody would be a potent inhibitor of PI3K signaling in HER2+ cells and, as such, induce significant growth inhibition in the absence of a direct antagonist of HER2. Thus, we tested the combination of LJM716 and the p110α inhibitor BYL719 in an 18-cancer cell line panel enriched with HER2 gene-amplified and PIK3CA mutant cells. Treatment with LJM716 alone inhibited proliferation, defined as >25% growth inhibition relative to control, in 6 of 18 (33%) cell lines as measured by the cell content of ATP (CellTiterGlo assay). Treatment with BYL719 induced >25% growth inhibition in 9 of 18 (50%) cell lines.
particularly those with hotspot mutations (i.e., H1047R, E545K) in PIK3CA (Fig. 4A, cell lines marked red). In 12 of 18 (67%) cell lines, treatment with the combination of LJM716 with BYL719 resulted in >25% growth inhibition (Fig. 4A). Combination activity exceeded that enacted by either agent in isolation in 11 of 18 (61%) cell lines. Analysis using the Chalice software package confirmed that combination treatment resulted in synergistic action of the 2 compounds (Supplementary Fig. S1). We confirmed these results in a second assay where cells are plated in monolayer followed by crystal violet staining. We observed a statistical decrease in growth of 4 of 5 HER2+ breast cancer cell lines treated with LJM716 and BYL719 compared with either single agent (Fig. 4B and Supplementary Fig. S2). Similar results were observed in single cells plated in 3D Matrigel and assessed for colony formation for 14 to 21 days, where 5 of 5 cell lines treated with LJM716 and BYL719 exhibited a statistically larger reduction in growth compared with either single agent (Fig. 4C and Supplementary Fig. S3). Finally, we examined the effect of the combination and single drugs on cell signaling at 1 to 24 hours. Treatment with BYL719 as a single agent increased P-HER3 in all 4 cell lines examined (Fig. 4D), consistent with the reported observation that inhibition of PI3K/AKT results in compensatory upregulation of active HER3 (24, 25). BYL719 reduced both S473 and T308 P-AKT, although in some cases this inhibition was partial. In BT474 and MDA361 cells, more potent inhibition of S473 P-AKT was achieved with the combination of LJM716/BYL719 (at 24 hours) than with either single agent. A similar result was observed with HCC1954 cells treated for 1 hour with the combination (Fig. 4D). Treatment with the combination did not affect P-ERK in 3 of the 4 cell lines.

**Combination of PI3Kα inhibitor and HER3 antibody inhibits growth of HER2+ xenografts**

Herein, we extended the in vitro observations (Fig. 4) to established tumors in mice. We initially investigated the effect short-term treatment of the HER3 antibody LJM716 and the PI3Kα inhibitor BYL719 had on xenografts to examine if synergistic changes in biomarkers of PI3/AKT pathway activity occurred in vivo. We treated athymic mice with established MDA453 and HCC1954 xenografts with vehicle, LJM716, BYL719, or the combination for 3 days. Tumors were harvested and subjected to immunoblot analysis. In HCC1954 xenografts treated with the combination, there was a more pronounced inhibition of T308 and S473 P-AKT, P-GSK3α/β, and P-S6 compared with tumors in mice treated with either single agent (Fig. 5A).

Next, we determined the effect of treatment in mice bearing either NCI-N87 gastric or MDA453 breast cancer xenografts. Athymic mice bearing NCI-N87 xenografts of ≥250 mm³ were randomized to therapy with vehicle, BYL719, LJM716, or the combination of both inhibitors. BYL719 and the combination of BYL719/LJM716 but not LJM716 alone inhibited growth of NCI-N87 tumors. After 48 days of continuous dosing, tumor volume in the group treated with both inhibitors was significantly smaller than in mice treated with the p110α inhibitor (P = 0.038, Mann–Whitney rank sum test; Fig. 5B). NCI-N87 tumors in mice treated with LJM716, BYL719, or the combination of the 2 exhibited significantly reduced S473 P-AKT.
Figure 4. LJM716 and p110α inhibitor synergistically inhibit tumor cell growth and PI3K. A, heatmap representing percent growth inhibition for the listed cell lines 5 days after treatment with 33 nmol/L (5 μg/mL) of LJM716, 330 nmol/L BYL719 or the combination, relative to untreated cells as assessed by the CellTiterGlo Assay. Values for LJM716 were the average of 2 independent dose-titration curves. Synergistic inhibition (synergy score > 2.0) was observed for the following cell lines: EFM192A, AU565, SKBR-3, BT474, MDA361, and MDA453 (all with HER2 gene amplification). Percent inhibition relative to immunoglobulin G–treated (control) cells is visualized in the form of a heatmap colored from blue (0% inhibition) to red (100% inhibition). Cell lines harboring PIK3CA hotspot mutations are highlighted in red. B, cells were plated (1–5 × 10^4 cells/well) in 6-well plates and treated in triplicate with DMSO, 10 μg/mL LJM716, and 1 μmol/L BYL719. Media and drugs were replenished every 3 to 4 days. Cells were stained with crystal violet when the DMSO-treated (control) monolayers became confluent, ranging from 14 to 21 days. Quantification of integrated intensity (% control) is shown (*, P < 0.05, t-test). C, cells were seeded in Matrigel and allowed to grow in the absence or presence of 10 μg/mL LJM716 and/or 1 μmol/L BYL719 as indicated. Cell media and drugs were replenished every 3 days. Images shown were recorded 15 to 19 days after seeding. (Continued on the following page.)
levels compared with tumors in control mice (Supplementary Fig. S4). Similar results were obtained in mice with MDA453 xenografts (≥250 mm³). These tumors are resistant to trastuzumab and harbor HER2 gene amplification, H1047R PIK3CA and a hemizygous deletion of PTEN. Both LJM716 and BYL719 as single agents inhibited MDA453 tumor growth, whereas the combination induced complete tumor regression in 10 of 10 mice after only 3 weeks of therapy (Fig. 5C). After achieving a
complete response, treatment was stopped. After 15 weeks of follow up, no mice exhibited a tumor recurrence.

We finally examined the activity of the combination of the HER3 antibody and the PI3Kα inhibitor with or without the HER2 antibody trastuzumab in an HER2-dependent, trastuzumab-sensitive xenograft. Mice bearing large BT474 xenografts (≥400 mm³) were treated with vehicle, BYL719, trastuzumab/BYL719, trastuzumab/LJM716, LJM716/BYL719, or BYL719/trastuzumab/LJM716. Mice in all these 4 groups exhibited rapid tumor regressions within 24 days of therapy (Fig. 6A). Thirty weeks after treatment discontinuation, 5 of 8 (63%) mice in the BYL719/trastuzumab/LJM716 exhibited tumor recurrences (≥200 mm³), whereas >85% of mice in all other groups did so (P = 0.0160, log-rank test; Fig. 6B). Moreover, 6 of 7 (86%) mice treated with trastuzumab/BYL719, 5 of 6 (83%) mice treated with trastuzumab/LJM716, and 6 of 6 (100%) mice treated with LJM716/BYL719; whereas only 1 of 7 (14%) mice treated with the triple drug combination had to be euthanized due to tumors reaching ≥2,000 mm³ in volume. This translated to a significant increase in survival in mice treated with the triple therapy compared with mice treated with various dual therapies (Fig. 6C).

Discussion

The HER2 receptor does not have a known activating ligand. Its tyrosine kinase activity can be induced by ligand-induced dimerization with the ERBB coreceptors EGFR and HER3 and/or by ligand-independent homo- and hetero-oligomerization as a result of gene amplification and protein overexpression (26). Heregulin binds to HER3, causing a change from a closed to an open conformation exposing the dimerization loop in subdomain II of the receptor ectodomain that, in turn, leads to the formation of HER2-HER3 dimers. In HER2-overexpressing cells and tumors, HER2 and HER3 are constitutively phosphorylated in the absence of added ligands (9). HER3 neutralizing antibodies screened for their ability to inhibit ligand binding to HER3 are in clinical development in patients

---

Figure 6. Combination of p110α inhibitor, HER3 antibody, and trastuzumab improves survival. A, female athymic mice were injected with BT474 cells as indicated in Materials and Methods. Once tumors reached a volume of ≥400 mm³, they were randomized to treatment with vehicle (controls) or the indicated combinations of 20 mg/kg LJM716, 20 mg/kg trastuzumab, and 30 mg/kg BYL719. Treatment was administered for 24 days. Tumor diameters were measured 2 to 3 times a week with calipers and volume in mm³ was calculated. Each data point represents the mean tumor volume in mm³ ± SEM. B and C, after 24 days, treatment was discontinued and mice were monitored for tumor recurrence. The x-axis indicates the number of weeks after treatment discontinuation. B, plot of tumor-free mice over time after termination of therapy; tumors ≥200 mm³ in volume were scored as recurrences. C, plot of overall mouse survival. Per institutional guidelines, mice were sacrificed once tumor burden was ≥2,000 mm³.
with solid tumors (27–29). As a single therapy, these antibodies have been shown to inhibit heregulin-dependent cancer cells but are less effective at inhibiting growth of HER2+ xenografts (17, 28). This supports the notion that HER2-overexpressing cancer cells also rely on constitutive, ligand-independent HER2-HER3 and/or HER2-EGFR dimers for tumor progression. LJM716 was designed to inhibit both ligand-independent and ligand-induced HER3 signaling. The crystal structural of the Fab fragment of LJM716 bound to the HER3 ectodomain reveals that the antibody binds a complex epitope on subdomains II and IV of HER3 that locks the receptor’s extracellular domain in the tethered, closed conformation (14). We show herein that LJM716 inhibits dimerization between HER2 and HER3 in vivo (Fig. 2) and, as a single agent, inhibits the growth of HER2-overexpressing breast and gastric cancer xenografts (Figs. 3A and 5B). To our knowledge, this is the first report of an HER3 neutralizing antibody with preclinical activity as a single drug against HER2 gene-amplified tumors in vivo. We speculate LJM716 should be able to disrupt other PI3K-activating HER3-containing dimmers, where HER2 is not the kinase that phosphorylates HER3. Examples include EGFR, MET, IGF-IR, FGFR, Src, and others kinases, which can be investigated in future studies.

HER2-overexpressing cells rely on HER2-HER3 dimers for potent activation of PI3K/AKT. In turn, PI3K signaling is critical for the viability and progression of HER2+ cancer cells. Indeed, HER2-directed therapies should inhibit PI3K downstream HER2 to inhibit growth of HER2-dependent cancer cells (30, 31). In tumor cells driven by HER2 or the rat homolog Neu, PIP3 formation is mediated by the catalytic activity of the p110α isozyme, encoded by the PIK3CA gene. Genetic ablation of p110α blocks tumor formation in transgenic mice expressing the Neu oncogene in the mammary gland (32). Consistent with these data, HER2+ tumor cells in culture are highly sensitive to PI3K inhibitors (33–35). Further supporting the reliance of HER2+ cancers on PI3K signaling downstream, a significant fraction of HER2-enriched breast tumors in the TCGA database also harbor activating mutations in PIK3CA (36). It is unclear if HER2+ tumor cells with PI3K pathway mutations have a more virulent phenotype than HER2+ tumors without those alterations. However, PI3K pathway mutations, including loss of PTEN, have been associated with resistance to anti-HER2 therapies (37–40). Although PI3K pathway antagonists are potent inhibitors of HER2-overexpressing cancer cells (34, 35), feedback upregulation of total and activated HER3 has been shown to dampen the full antitumor action of these inhibitors (24). Thus, in this work we examined dual blockade of the HER2/HER3/PI3K axis with an antibody targeting HER3 and a PI3Kα inhibitor. The combination of LJM716 with BYU719 was highly active against several HER2 gene-amplified cell lines irrespective of their PI3K mutation status (Fig. 4). As a single agent, LJM716 effectively inhibited P-HER3 and P-AKT in HER2+ cancer cell lines. In some instances, we observed a recovery of P-AKT 24 hours after treatment with LJM716 (Fig. 1). However, LJM716 in combination with BYU719 induced more sustained inhibition of P-AKT and downstream effectors than either drug alone (Figs. 4D and 5C), suggesting this approach overcomes the reactivation of HER3 triggered by inhibition of PI3K/PI3K (17, 24, 25). Using this combination of HER3 and PI3Kα antagonists in the absence of a direct HER2 inhibitor, we observed complete elimination of trastuzumab-resistant MDA453 xenografts (Fig. 5B). Whether this combination has similar activity in patients with HER2+ breast cancer progressing on trastuzumab will require further clinical investigation.

It is increasingly accepted that for optimal inhibition of HER2 function in HER2+ breast cancer cells, treatment with at least 2 anti-HER2 drugs is required. Currently, the combinations of trastuzumab and lapatinib and of trastuzumab and pertuzumab are approved by the FDA for use in patients with metastatic HER2+ breast cancer. These 3 drugs interact with HER2 directly. Other plausible approaches for dual blockade of HER2 are concurrent use of a direct inhibitor of HER2 with a second drug targeted to a different component of the HER2/HER3/PI3K axis. Such combinations would include trastuzumab and an HER3 antibody or trastuzumab and a PI3K inhibitor, for example. Support for the first combination is shown in Fig. 3A, where the combination of trastuzumab/ LJM716 was clearly superior to each antibody alone against BT474 xenografts. Recent preclinical reports support efficacy of the combination of trastuzumab (or lapatinib) with PI3K inhibitors (24, 41–43), which are currently being tested in clinical trials. Based on the data presented herein, we propose that the combination of an HER3 antibody that eliminates both ligand-dependent and -independent HER3 dimerization and a p110α inhibitor is another strategy for dual blockade of the HER2/HER3/PI3K axis in HER2-overexpressing breast cancer. This dual approach should be explored clinically in patients with this breast cancer subtype that have progressed on trastuzumab.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J.T. Garrett, C.R. Sutton, R. Kurupi, S.D. Collins, Q. Sheng, J. Wallweber, C.L. Arteaga
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): J.T. Garrett, S.A. Ettenberg, S.D. Collins, Q. Sheng, J. Wallweber, L. DeFazio-Eli, C.L. Arteaga
Writing, review, and/or revision of the manuscript: J.T. Garrett, C.U. Bialucha, S.A. Ettenberg, Q. Sheng, J. Wallweber, L. DeFazio-Eli, C.L. Arteaga
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J.T. Garrett, C.R. Sutton, R. Kurupi, S.A. Ettenberg, S.D. Collins, Q. Sheng, C.L. Arteaga
Study supervision: J.T. Garrett, S.A. Ettenberg, Q. Sheng, C.L. Arteaga

Acknowledgments
The authors thank J. Winslow and A. Chenna for their experimental and analytical contributions to VeraTag HER3-PI3K and VeraTag phospho-HER3 experiments. The authors also thank MorphoSys for their contributions in isolation and characterization of the LJM716 antibody.

Grant Support
This work was supported in part by ACS 118813-PF-10-070-01-TBG (J.T. Garrett) and DOD BC093376 (J.T. Garrett) postdoctoral fellowship awards, R01 Grant CA80195 (C.L. Arteaga), American Cancer Society (ACS) Clinical Research Professorship Grant CRP-07-234 (C.L. Arteaga), Breast Cancer Specialized Support.
Program of Research Excellence (SPORE) P50 CA98131, and S.G. Komen for the Cure Foundation grant SAC100013 (C.L. Arteaga). C.L. Arteaga is supported by a Stand Up to Cancer Dream Team Translational Research Grant, a Program of the Entertainment Industry Foundation (USC—ACR-ITDO99).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked

advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 23, 2013; revised July 13, 2013; accepted July 30, 2013; published OnlineFirst August 5, 2013.

References

33. Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H, et al. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-


Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers


Cancer Res  Published OnlineFirst August 5, 2013.

Updated version  Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-13-1191

Supplementary Material  Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2013/08/12/0008-5472.CAN-13-1191.DC1

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.